Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,227
  • Shares Outstanding, K 3,355
  • Annual Sales, $ 16,800 K
  • Annual Income, $ -43,320 K
  • EBIT $ -31 M
  • EBITDA $ -28 M
  • 60-Month Beta 3.93
  • Price/Sales 4.60
  • Price/Cash Flow N/A
  • Price/Book 1.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-4.00
  • Number of Estimates 4
  • High Estimate $-3.22
  • Low Estimate $-4.49
  • Prior Year $-3.20
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.98 +15.22%
on 03/20/26
26.47 -13.05%
on 04/07/26
-0.84 (-3.50%)
since 03/17/26
3-Month
18.19 +26.53%
on 02/17/26
29.25 -21.32%
on 03/13/26
-0.05 (-0.20%)
since 01/16/26
52-Week
9.00 +155.72%
on 06/02/25
54.29 -57.61%
on 07/07/25
+4.61 (+25.08%)
since 04/17/25

Most Recent Stories

More News
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics Announces CFO Transition

DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos...

PTHS : 23.02 (+0.07%)
HRZN : 4.38 (-1.13%)
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

DURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient...

PTHS : 23.02 (+0.07%)
HRZN : 4.38 (-1.13%)
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients...

PTHS : 23.02 (+0.07%)

Business Summary

Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 23.52
2nd Resistance Point 23.39
1st Resistance Point 23.20
Last Price 23.02
1st Support Level 22.88
2nd Support Level 22.75
3rd Support Level 22.56

See More

52-Week High 54.29
Fibonacci 61.8% 36.99
Fibonacci 50% 31.65
Fibonacci 38.2% 26.30
Last Price 23.02
52-Week Low 9.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.